Patient management of cerebral origin spasticity with intrathecal baclofen.
Controlled, continuous intrathecal infusion of baclofen injection relieves severe spasticity for a wide range of patients. This therapy has become a standard treatment option in spasticity management programs. Multidisciplinary teams, coordinated by an experienced neuroscience practitioner, provide treatment in five phases. Experience from clinical trials and commercial use of this treatment provides a guide for others who are initiating this therapy at their facility. Further prospective research is needed to accurately determine best clinical practice guidelines for cost effective use of this therapy.
Rawlins
P
P
Galichia Research Institute/Research Institute of Kansas, USA. Pantict@aol.com
D001418:Baclofen / Q000627:therapeutic use*; D001930:Brain Injuries / Q000150:complications*; D002547:Cerebral Palsy / Q000150:complications*; D016903:Drug Monitoring; D006757:Hospital Units; D006801:Humans; D015918:Infusion Pumps, Implantable; D007263:Infusions, Parenteral; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology / Q000451:nursing*; D010343:Patient Admission; D018579:Patient Selection; D013131:Spine
D009125:Muscle Relaxants, Central; D001418:Baclofen